Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma)

Annals of the Rheumatic Diseases

Volumn 60, Issue 5, 2001, Pages 487-494

  Matucci Cerinic, M ^a   Giacomelli, R ^b   Pignone, A ^a   Cagnoni, M ^a   Generini, S ^a   Casale, R ^c   Cipriani, P ^b   Del Rosso, A ^a   Tirassa, P ^f   Konttinen, Y T ^d   Kahaleh, B M ^e   Fan, P S ^e   Paoletti, M ^a   Marchesi, C ^a   Aloe, L ^f   Cagnoni, M L ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

^c IRCCS   (Italy)

^d UNIVERSITY OF HELSINKI   (Finland)

^e MEDICAL COLLEGE OF OHIO   (United States)

^f CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; DIPEPTIDYL CARBOXYPEPTIDASE; NERVE GROWTH FACTOR; NEUROPEPTIDE Y; RHEUMATOID FACTOR; VASOACTIVE INTESTINAL POLYPEPTIDE; VON WILLEBRAND FACTOR;

ADULT; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEART DISEASE; HUMAN; LABORATORY TEST; LUNG FUNCTION TEST; LUNG PRESSURE; MALE; PATHOGENESIS; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; SKIN MANIFESTATION; SYSTEMIC SCLEROSIS;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; NERVE GROWTH FACTOR; NEUROPEPTIDE Y; NEUROPEPTIDES; SCLERODERMA, SYSTEMIC; SKIN; STATISTICS, NONPARAMETRIC; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0035022631     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.60.5.487     Document Type: Article

References (51)

1. The vascular involvement in systemic sclerosis
2. Biology of the scleroderma fibroblast
3. Immune abnormalities in systemic sclerosis
4. Systemic sclerosis (scleroderma)
5. Peripheral neuropathy in systemic sclerosis. The median nerve as a target structure
6. The nervous system in systemic sclerosis (scleroderma): Clinical and pathogenetic features
7. Raynaud's phenomenon and scleroderma: Dysregulated neuroendothelial control of vascular tone
8. Nerve growth factor: From neurotrophin to neurokine
9. The nerve growth factor: Biochemistry, synthesis, and mechanism of action
10. Regulation of substance P by NGF: Disruption by capsaicin
11. Human fibroblast cells synthesize and secrete nerve growth factor
12. Mast cells synthesize, store and release nerve growth factor
13. NGF production by lymphocytes
14. Growth regulated synthesis and secretion of biologically active nerve growth factor by human keratinocytes
15. Nerve growth factor and autoimmune rheumatic diseases
16. Nerve growth factor circulating levels are increased in Kawasaki disease: Correlation with disease activity and reduced angiotensin converting enzyme levels
17. Nerve growth factor autoantibodies and NGF in the synovial fluid: Implications in spondyloarthropathies
18. Circulating NGF is directly correlated with disease activity in juvenile chronic arthritis
19. NGF and autoimmune diseases
20. Nerve growth factor and mast cell distribution in the skin of patients with systemic sclerosis
21. Sensory neuropeptides and rheumatic diseases
22. Neuropeptides and hormones in arthritis
23. Overexpression of NGF in epidermis disrupts the distribution and properties of sympathetic innervation in footpads
24. Substance P and vasoactive intestinal peptide in patients with progressive scleroderma. Determination of plasma level before and after autogenic training
25. Plasma noradrenaline and neuropeptide Y may not be of primary importance in the pathophysiology of cardiac involvement in systemic sclerosis
26. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis
27. An enzyme-linked immunoassay for nerve growth factor (NGF): A tool for studying regulatory mechanisms involved in NGF production in brain and in peripheral tissues
28. Multiple sclerosis patients express increased levels of b-nerve growth factor in cerebrospinal fluid
29. Cholecystokinin-8 regulates NGF concentrations in adult mouse brain through a mechanism involving CCKA and CCKB receptors
30. The nerve growth factor: Purification as a 30,000-molecular-weight protein
31. Neuropeptides of the autonomic nervous system in Sjögren syndrome
32. Antiendothelial cell antibodies in systemic sclerosis: Correlation with vascular involvement
33. A modified scleroderma skin scoring method
34. Arthritis in scleroderma
35. Angiotensin converting enzyme: An in vivo and in vitro marker of endothelial injury
36. Beta-NGF as a mediator of the acute phase response in vivo
37. The role of nerve growth factor in a model of visceral inflammation
38. Nerve growth factor: Stimulation of polymorphonuclear leukocyte chemotaxis
39. Nerve growth factor is performed in and activates human peripheral blood eosinophils
40. Nerve growth factor and cytokines mediate lymphoid tissue-induced neurite outgrowth from mouse superior cervical ganglia in vitro
41. Contribution of IL-1 beta to the inflammation-induced increase in NGF levels and inflammatory hyperalgesia
42. Phenotypic modification of primary sensory neurons: Role of nerve growth factor in the production of persistent pain
43. Basophil priming by neurotrophic factors. Activation through the trk receptors
44. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity
45. Successful treatment of esophageal dismotility and Raynaud's phenomenon in systemic sclerosis and achalasia by transcutaneous nerve stimulation. Increase in plasma VIP concentration
46. The antioxidant enzymes glutathione peroxidase and catalase increase following traumatic brain injury in the rat
47. Role of NGF in oxidant homeostasis: Glutathione metabolism
48. Increased uptake of L-cysteine and L-cystine by NGF in rat pheocromocytoma cells
49. Regulation of gamma-glutamylcysteine synthetase activity by nerve growth factor
50. Protective role of nerve growth factor against postischemic dysfunction of sympathetic coronary innervation